Altogether, these results demonstrated that antagonising circ-Ntrk2 could alleviate PAH by inhibiting PASMC proliferation and reversing pulmonary vascular remodelling through the miR-296-5p/TGF-β1/p38 MAPK signal transduction axis (Fig. 7). The gene discussed is NTRK2; the disease is pulmonary arterial hypertension.